P205 | THE PROGNOSTIC VALUE AND CLINICAL IMPACT OF ASXL1 MUTATIONS IN MYELOFIBROSIS: A RETROSPECTIVE COLLECTION

BACKGROUD: Next-generation sequencing (NGS) has unveiled novel non-driver mutations in myelofibrosis (MF), beyond the common driver mutations. Among these, ASXL1 gene is the most frequently involved and is considered within the high-molecular risk (HMR) group alongside EZH2, SRSF2, IDH1/2, and U2AF...

Full description

Bibliographic Details
Published in:	Haematologica
Main Authors:	A. Laganà, E. Rossi , G. Iaquinta , F. Ramundo, F. Frioni, M. Rossi, L. Maurillo, R. Latagliata, S.L. Crescenzi, A. Tamburini, K. Paciaroni, M. Santopietro, C. Tatarelli, P. Grammatico, V. De Stefano, P. Chiusolo, and M. Breccia, N/A *
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-09-01
Online Access:	https://haematologica.org/article/view/12402

Similar Items

DP126 | REAL-LIFE STUDY ON VERY ELDERLY PATIENTS WITH POLYCYTHEMIA VERA: EXPERIENCE FROM THE NPM PH-NEGATIVE LATIAL GROUP
by: C. Tatarelli, et al.
Published: (2025-09-01)

C097 | MDS/MPN OTHER THAN CMML: AN ITALIAN COOPERATIVE STUDY
by: L. Guarnera, et al.
Published: (2025-09-01)

Analysis of somatic mutations in the <i>JAK2</i>, <i>CALR</i>, <i>MPL</i> and <i>ASXL1</i> genes and evaluation of their impact on the survival of patients with myelofibrosis
by: T. N. Subbotina, et al.
Published: (2023-03-01)

Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation
by: Patrizia Chiusolo, et al.
Published: (2022-09-01)

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
by: Xin Yan, et al.
Published: (2023-04-01)

Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021
by: Andrea Bacigalupo, et al.
Published: (2021-05-01)

S205: INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS
by: Hélène Gleitz, et al.
Published: (2023-08-01)

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes
by: Brady L. Stein, et al.
Published: (2011-10-01)

The expression of ASXL3 in prostate cancer
by: ZHANG Jinhui, et al.
Published: (2024-03-01)

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
by: Maya C. Ayoub, et al.
Published: (2023-11-01)

Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib
by: Alessandro Laganà, et al.
Published: (2025-01-01)

Integrative analysis of ASXL family genes reveals ASXL2 as an immunoregulatory molecule in head and neck squamous cell carcinoma
by: Qian Liu, et al.
Published: (2024-12-01)

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish
by: Evisa Gjini, et al.
Published: (2019-05-01)

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms
by: Hélène F.E. Gleitz, et al.
Published: (2022-08-01)

P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML
by: A. Bidikian, et al.
Published: (2022-06-01)

P985: THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF
by: G. Coltro, et al.
Published: (2022-06-01)

Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
by: Yu-Kun Xia, et al.
Published: (2020-07-01)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
by: F. Palandri, et al.
Published: (2022-06-01)

Mutations of ASXL1 and TET2 in aplastic anemia
by: Jinbo Huang, et al.
Published: (2015-05-01)

Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value
by: Marta Pratcorona, et al.
Published: (2012-03-01)

Role of splenectomy in the treatment of myelofibrosis
by: A L Melikian, et al.
Published: (2013-08-01)

Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients
by: P. Akyol, et al.
Published: (2020-10-01)

<i>ASXL1/TET2</i> genotype-based risk stratification outperforms <i>ASXL1</i> mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia
by: Clifford M. Csizmar, et al.
Published: (2024-06-01)

ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?
by: Adam M. Dinan, et al.
Published: (2017-10-01)

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives
by: Massimo Breccia, et al.
Published: (2024-07-01)

A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease
by: Steven M. Johnson, et al.
Published: (2023-06-01)

P199 | REAL-WORLD INSIGHTS INTO MOLECULAR PREDICTORS OF RESPONSE AND RESISTANCE TO JAK INHIBITORS IN MYELOFIBROSIS
by: V. Boldrini, et al.
Published: (2025-09-01)

P059 | SPLENOMEGALY IN DE NOVO ACUTE MYELOID LEUKEMIA IS ASSOCIATED WITH ASXL1 MUTATIONS AND PECULIAR GENE EXPRESSION AND CLINICAL PROFILE.
by: F. Tarantini, et al.
Published: (2025-09-01)

Primary myelofibrosis in rheumatic diseases
by: Vladimir Ivanovich Vasilyev, et al.
Published: (2013-04-01)

MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
by: Francesco Lococo, et al.
Published: (2013-06-01)

P085 | ASXL1 MUTATIONS DETERMINE INFERIOR OUTCOME IN LOWER-RISK MYELODYSPLASTIC SYNDROMES:MONOCENTRIC REAL-LIFE DATA
by: D. Barraco, et al.
Published: (2025-09-01)

P1001: DNMT3A/TET2/ASXL1 MUTATIONS DETERMINE THROMBOTIC RISK IN POLYCYTHAEMIA VERA
by: A. Segura Diaz, et al.
Published: (2022-06-01)

Asxl1 loss in mice leads to microcephaly by regulating neural stem cell survival
by: Hyeju Kim, et al.
Published: (2025-12-01)

The metastable HCl · 6H<sub>2</sub>O phase – IR spectroscopy, phase transitions and kinetic/thermodynamic properties in the range 170–205 K
by: S. Chiesa, et al.
Published: (2013-12-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Massimo Breccia, et al.
Published: (2011-05-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

DP128 | NEUTROPHIL-TO-LYMPHOCYTE RATIO AT DIAGNOSIS PREDICTS VENOUS THROMBOSIS IN PREFIBROTIC PRIMARY MYELOFIBROSIS: RESULTS FROM AN ITALIAN COOPERATIVE STUDY
by: F. Cavalca, et al.
Published: (2025-09-01)

Genetic profile of ASXL1 gene in risk assessment in acute myeloid leukemia
by: Salem Ahmed Bamusa, et al.
Published: (2025-07-01)